MCID: IRR002
MIFTS: 62

Irritable Bowel Syndrome

Categories: Gastrointestinal diseases

Aliases & Classifications for Irritable Bowel Syndrome

MalaCards integrated aliases for Irritable Bowel Syndrome:

Name: Irritable Bowel Syndrome 12 76 37 43 44 15 63 73
Ibd 12 3
Irritable Colon 12
Psychogenic Ibs 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9778
ICD10 33 K58 K58.9 K58.0
ICD9CM 35 564.1
MeSH 44 D043183
NCIt 50 C82343
KEGG 37 H01615
UMLS 73 C0022104

Summaries for Irritable Bowel Syndrome

MedlinePlus : 43 Irritable bowel syndrome (IBS) is a problem that affects the large intestine. It can cause abdominal cramping, bloating, and a change in bowel habits. Some people with the disorder have constipation. Some have diarrhea. Others go back and forth between the two. Although IBS can cause a great deal of discomfort, it does not harm the intestines. IBS is common. It affects about twice as many women as men and is most often found in people younger than 45 years. No one knows the exact cause of IBS. There is no specific test for it. Your doctor may run tests to be sure you don't have other diseases. These tests may include stool sampling tests, blood tests, and x-rays. Your doctor may also do a test called a sigmoidoscopy or colonoscopy. Most people diagnosed with IBS can control their symptoms with diet, stress management, probiotics, and medicine. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Irritable Bowel Syndrome, also known as ibd, is related to dyspepsia and fibromyalgia, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Irritable Bowel Syndrome is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian rythm related genes. The drugs Esomeprazole and Amitriptyline have been mentioned in the context of this disorder. Affiliated tissues include colon, testes and brain, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A syndrome that is a functional bowel disorder characterized by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits in the absence of any detectable organic cause.

CDC : 3 Inflammatory Bowel Disease (IBD) is a broad term that describes conditions characterized by chronic inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn’s disease. Inflammation affects the entire digestive tract in Crohn’s disease and only the large intestine (also called the colon) in ulcerative colitis. Both illnesses involved an abnormal response to the body’s immune system.

PubMed Health : 63 About irritable bowel syndrome: The typical symptoms of irritable bowel syndrome (IBS) include abdominal pain, constipation and diarrhea. Although IBS is not dangerous, the symptoms can be very painful and bothersome. Most people who have IBS have a mild form which they can cope with quite well without getting any treatment. But some people have symptoms that are so severe they significantly affect their everyday lives and cause distress. There is no cure for IBS. But over time, many people find out what helps and what makes things worse. And there are a number of different ways to relieve the symptoms.

Wikipedia : 76 Irritable bowel syndrome (IBS) is a group of symptoms—including abdominal pain and changes in the... more...

Related Diseases for Irritable Bowel Syndrome

Diseases related to Irritable Bowel Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 191)
# Related Disease Score Top Affiliating Genes
1 dyspepsia 31.6 CCK HTR3A SLC6A4 TRPV1
2 fibromyalgia 31.4 CRH HTR3A SLC6A4
3 gastroesophageal reflux 30.8 CCK MLN TRPV1 VIP
4 celiac disease 1 30.8 CCK IL10 TGM2 TNF
5 chronic fatigue syndrome 30.7 CRH IL10 SLC6A4 TNF
6 bulimia nervosa 30.7 CCK HTR3A SLC6A4
7 generalized anxiety disorder 30.7 CRHR1 HTR3A SLC6A4 TPH1
8 depression 30.6 CRH CRHR1 HTR3A SLC6A4 TPH1
9 postcholecystectomy syndrome 30.0 CCK MLN
10 anxiety 29.7 CCK CRH CRHR1 CRHR2 HTR3A SLC6A4
11 cystitis 29.6 TAC1 TNF TRPV1
12 functional diarrhea 29.6 HTR3A HTR4 HTR7 TAC1
13 constipation 29.5 CCK HTR3A HTR4 MLN SLC6A4 TAC1
14 somatoform disorder 29.3 TAC1 TPH1 TRPV1
15 panic disorder 29.2 CCK CRH CRHR1 CRHR2 HTR3A SLC6A4
16 dermatitis, atopic 29.2 IL10 TLR9 TNF TRPV1 VIP
17 vasomotor rhinitis 28.9 TAC1 TLR9 VIP
18 rhinitis 28.5 TLR9 TRPV1 VIP
19 inflammatory bowel disease 28.1 CHGA IL10 TAC1 TLR9 TNF TRPV1
20 gastrointestinal system disease 27.6 CCK CRH HTR4 IL10 MLN TLR9
21 asthma 27.2 CRH IL10 TAC1 TLR9 TNF TRPV1
22 isobutyryl-coa dehydrogenase deficiency 11.8
23 gastrointestinal defects and immunodeficiency syndrome 11.5
24 diarrhea 11.4
25 interstitial cystitis 11.4
26 fecal incontinence 11.3
27 acquired fructose intolerance 11.2
28 punctate inner choroidopathy 11.0 IL10 TNF
29 tropical endomyocardial fibrosis 10.9 IL10 TNF
30 postural orthostatic tachycardia syndrome 10.9
31 colonic disease 10.9
32 hereditary alpha tryptasemia syndrome 10.9
33 social phobia 10.8 CCK HTR3A SLC6A4
34 microscopic polyangiitis 10.8 IL10 TNF
35 pylorospasm 10.8 HTR4 MLN
36 multifocal choroiditis 10.8 IL10 TNF
37 early-onset schizophrenia 10.8 HTR3A SLC6A4 TNF
38 gastroparesis 10.7 CCK HTR3A MLN
39 tungiasis 10.7 IL10 TNF
40 endomyocardial fibrosis 10.7 IL10 TNF
41 eating disorder 10.6 CCK CRH SLC6A4
42 mitral valve disease 10.6 IL10 SLC6A4 TPH1
43 pancreas disease 10.6 CCK TNF TRPV1
44 gallbladder disease 10.6 CCK IL10 MLN
45 transient hypogammaglobulinemia 10.6 IL10 TNF
46 atypical depressive disorder 10.5 CRH HTR7 SLC6A4
47 chronic pulmonary heart disease 10.5 HTR7 SLC6A4 TNF
48 colitis 10.5
49 binswanger's disease 10.4 CHGA CRH VIP
50 functional colonic disease 10.4 HTR4 HTR7 MLN

Comorbidity relations with Irritable Bowel Syndrome via Phenotypic Disease Network (PDN): (show all 26)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Anxiety
Atrophic Gastritis Bronchitis
Chronic Myocardial Ischemia Deficiency Anemia
Dependent Personality Disorder Dyskinesia of Esophagus
Dysthymic Disorder Esophagitis
Generalized Anxiety Disorder Hypertension, Essential
Hypochondriasis Hypothyroidism
Intermediate Coronary Syndrome Intestinal Obstruction
Iron Deficiency Anemia Ischemic Heart Disease
Major Depressive Disorder Mitral Valve Disease
Osteoporosis Paralytic Ileus
Protein-Energy Malnutrition Somatization Disorder

Graphical network of the top 20 diseases related to Irritable Bowel Syndrome:



Diseases related to Irritable Bowel Syndrome

Symptoms & Phenotypes for Irritable Bowel Syndrome

UMLS symptoms related to Irritable Bowel Syndrome:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, vomiting following gastrointestinal surgery, gastrointestinal gas

GenomeRNAi Phenotypes related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 HTR3A MLN SLC6A4
2 Decreased viability GR00381-A-3 9.28 HTR3A MLN SLC6A4
3 Decreased viability GR00402-S-2 9.28 HTR3A MLN SLC6A4

MGI Mouse Phenotypes related to Irritable Bowel Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 TGM2 VIP TNF TPH1 SLC6A4 TRPV1
2 homeostasis/metabolism MP:0005376 10.3 TGM2 VIP TLR9 TNF OCLN TPH1
3 endocrine/exocrine gland MP:0005379 10.18 TGM2 VIP TNF OCLN SLC6A4 IL10
4 cardiovascular system MP:0005385 10.17 TAC1 TRPV1 TGM2 VIP TNF TPH1
5 nervous system MP:0003631 10.03 TRPV1 TGM2 TNF OCLN SLC6A4 IL10
6 integument MP:0010771 9.97 TAC1 TRPV1 TNF TPH1 SLC6A4 IL10
7 adipose tissue MP:0005375 9.95 TRPV1 TNF TPH1 CRHR2 HTR4 CRH
8 no phenotypic analysis MP:0003012 9.76 TRPV1 TGM2 TNF IL10 CRHR1 CCK
9 renal/urinary system MP:0005367 9.56 TAC1 TRPV1 TGM2 TLR9 CCK HTR3A
10 respiratory system MP:0005388 9.17 VIP TNF TPH1 IL10 CRHR1 HTR4

Drugs & Therapeutics for Irritable Bowel Syndrome

PubMedHealth treatment related to Irritable Bowel Syndrome: 63

There are a lot of different opinions about what can help relieve irritable bowel syndrome. Common recommendations include eating or avoiding certain foods and getting exercise. But most of this advice has not been tested in good-quality studies. If you ask different people who have IBS, it becomes clear that something that helps one person may end up making someone else’s symptoms worse. So it is best to try out different things and see for yourself if it helps.For example, someone who thinks that a particular type of food is making their symptoms worse can try to avoid eating it for a while. Some people have fewer symptoms if they eat their meals in smaller portions throughout the day. Keeping a diary can help you figure out whether doing specific things like exercising more or avoiding certain types of food have any effect. You can make a note of what you eat, how physically active you are, and how stressed you are over a longer period of time. It might be possible to recognize patterns after a while.There are also a number of different treatments that aim to relieve the symptoms. Because the causes of IBS are not clear, it is difficult to find suitable treatments. But research has suggested that at least some medications and treatments may help. Treatments for IBS include:Fiber supplements, for instance made from psylliumPeppermint oilProbioticsAnti-cramping medicationsMedications for constipation or diarrheaVarious medications, such as antibiotics or antidepressantsPsychological treatments, such as stress management or hypnosisBecause medications in particular can have a number of side effects and sometimes even make the symptoms worse, it is worth carefully considering the potential advantages and disadvantages of taking them.

Drugs for Irritable Bowel Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 346)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
2
Amitriptyline Approved Phase 4 50-48-6 2160
3
Citalopram Approved Phase 4,Phase 2 59729-33-8 2771
4
Loperamide Approved Phase 4,Phase 3,Phase 2,Not Applicable 53179-11-6 3955
5
Curcumin Approved, Investigational Phase 4,Phase 2 458-37-7 969516
6
Perphenazine Approved Phase 4 58-39-9 4748
7
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
8 Ramosetron Approved, Investigational Phase 4,Phase 3,Phase 2 132036-88-5
9
Rifaximin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 80621-81-4 6436173
10
Lubiprostone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 136790-76-6 656719
11
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-23-7 5754
12
Dopamine Approved Phase 4,Not Applicable 51-61-6, 62-31-7 681
13
Pantoprazole Approved Phase 4 102625-70-7 4679
14
Norepinephrine Approved Phase 4,Not Applicable 51-41-2 439260
15
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2 148553-50-8 5486971
16
Metronidazole Approved Phase 4 443-48-1 4173
17
Montelukast Approved Phase 4 158966-92-8 5281040
18
Trimebutine Approved Phase 4,Phase 2,Phase 3 39133-31-8
19
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774
20
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
21
Ebastine Approved, Investigational Phase 4 90729-43-4 3191
22
Ondansetron Approved Phase 4,Phase 3,Phase 2,Not Applicable 99614-02-5 4595
23
Eluxadoline Approved, Investigational Phase 4,Phase 2 864821-90-9
24
Mebeverine Approved, Investigational Phase 4 3625-06-7 62887
25
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
26
Pancrelipase Approved, Investigational Phase 4,Not Applicable 53608-75-6
27
Alverine Approved, Investigational Phase 4 150-59-4 3678
28
Simethicone Approved Phase 4,Phase 1 8050-81-5
29
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
30
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
31
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
32
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 77-92-9 311
33
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Not Applicable 1406-16-2
34
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 1 67-97-0 6221 5280795
35 Mosapride Investigational Phase 4,Phase 3,Phase 2 112885-41-3
36 Tiropramide Investigational Phase 4 55837-29-1 42262
37
Daidzein Experimental Phase 4 486-66-8 5281708
38
Genistein Investigational Phase 4 446-72-0 5280961
39
Maleic acid Experimental Phase 4 110-16-7 444266
40 Fenoverine Investigational Phase 4 37561-27-6
41 rifamycin SV Phase 4,Phase 3,Phase 2,Not Applicable
42 Analgesics Phase 4,Phase 3,Phase 2,Not Applicable
43 calcium channel blockers Phase 4,Phase 2,Not Applicable
44 Cathartics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Rifamycins Phase 4,Phase 3,Phase 2,Not Applicable
48 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Cholinergic Agents Phase 4,Phase 2,Not Applicable
50 Adrenocorticotropic Hormone Phase 4,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 699)
# Name Status NCT ID Phase Drugs
1 Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome Unknown status NCT02614963 Phase 4 Clostridium Butyricum;placebo
2 Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
3 Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome Unknown status NCT01629212 Phase 4 Tiropramide HCl 100mg;Octylonium bromide 20mg
4 Lactibiane Tolérance® in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance Unknown status NCT02728063 Phase 4
5 Pain Relief In Irritable Bowel Syndrome Unknown status NCT02573844 Phase 4 Proklama
6 Effect of Pentoxifylline on Tight Junctions (TJs) of Intestinal Mucosa in Patients With Irritable Bowel Syndrome(IBS) Unknown status NCT01542268 Phase 4 pentoxifylline;pentoxifylline placebo
7 Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome Unknown status NCT02565550 Phase 4
8 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
9 Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects Unknown status NCT02433847 Phase 4 Mosapride
10 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS) Unknown status NCT01779765 Phase 4
11 Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D Unknown status NCT01638208 Phase 4 VSL#3
12 Safety and Therapeutic Efficacy of Phosphate Enema (Kleen Enema) in Patients Undergoing Sigmoidoscopy Unknown status NCT02386904 Phase 4 Phosphate Enema (Kleen® Enema)
13 Effect of Ramosetron on Bowel Motility After Colorectal Resection Unknown status NCT01427127 Phase 4 Ramosetron
14 Gastric Functions & Proton Pump Inhibitor( PPI) Study Unknown status NCT00951431 Phase 4 Esomeprazole;Placebo
15 Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial Completed NCT00779493 Phase 4
16 Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS) Completed NCT01404923 Phase 4 anti spasmodic agents;alverine citrate, simeticone
17 An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome Completed NCT00401258 Phase 4 duloxetine
18 Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial) Completed NCT00934973 Phase 4 mebeverine;methylcellulose;placebo
19 Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
20 Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression Completed NCT01754493 Phase 4 Duloxetine
21 An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Completed NCT00961298 Phase 4 Duloxetine
22 Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome Completed NCT01331213 Phase 4 Pregabalin;Placebo
23 Manipulation of Visceral Hypersensitivity With Probiotic Bacteria in Irritable Bowel Syndrome Completed NCT01139736 Phase 4
24 Efficacy Evaluation of a Commercial Preparation Containing Lactobacillus Casei DG on the Reduction of the Painful Symptoms Related to the Irritable Bowel Syndrome (IBS). A Pilot Clinical Study Completed NCT02077699 Phase 4
25 Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use Completed NCT02959983 Phase 4 Eluxadoline;Placebo
26 A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients Completed NCT01225237 Phase 4 Ramosetron;Placebo
27 Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder Completed NCT01551225 Phase 4 Escitalopram
28 Validation of Surrogate Measures in Irritable Bowel Syndrome (IBS) Completed NCT00693732 Phase 4 Escitalopram treatment
29 An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation Completed NCT02590432 Phase 4 Linaclotide 290 micrograms;Linaclotide 145 micrograms;Linaclotide 72 micrograms
30 Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D) Completed NCT01316718 Phase 4 Mesalazine;Placebo
31 A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT00918411 Phase 4 Ramosetron;Placebo
32 Irritable Bowel Syndrome Evaluation and Treatment in Primary Care Completed NCT01641341 Phase 4 Bifidobacterium infantis;Pancrelipase;Nitazoxanide;Placebo
33 Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome Completed NCT01886781 Phase 4 Lactobacillus plantarum 299v;Placebo comparator
34 Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome Completed NCT00542295 Phase 4 alverine citrate and simeticone;placebo
35 Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists Completed NCT01144832 Phase 4 ebastine;placebo capsule
36 Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids Completed NCT02111603 Phase 4 Colesevelam
37 Comparative Efficacy and Safety of Fenoverine Completed NCT01507922 Phase 4 Fenoverine;Timebutine
38 Multi-strain Probiotic in the Management of IBS-D Completed NCT03251625 Phase 4 Probiotic Formula Capsule
39 Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome Completed NCT02026518 Phase 4
40 Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS Completed NCT00142987 Phase 4 Tegaserod
41 Study to Assess the Effect Of Alosetron On Mucosal Blood Flow Completed NCT00370032 Phase 4 alosetron
42 EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth Completed NCT00331994 Phase 4 Bacillus clausii;Metronidazole
43 Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D) Completed NCT00745004 Phase 4 Ondansetron;Placebo
44 Probiotic in Irritable Bowel Syndrome (IBS) Patients With Diarrhea Completed NCT01667627 Phase 4
45 Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders Completed NCT02566876 Phase 4 Mixture of three Bifidobacteria
46 Mode of Action of Moviprep Completed NCT01622972 Phase 4 Polyethyleneglycol
47 Lubiprostone in Patients With Multiple Sclerosis Associated Constipation Completed NCT01236534 Phase 4 Lubiprostone;Placebo
48 The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Motility in Healthy Volunteers Completed NCT02736734 Phase 4 CRH
49 Imaging the Effect of Experimental Stress on Small and Large Bowel Water During Fructose Absorption Completed NCT01763281 Phase 4 CRH;Placebo
50 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide

Search NIH Clinical Center for Irritable Bowel Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: irritable bowel syndrome

Genetic Tests for Irritable Bowel Syndrome

Anatomical Context for Irritable Bowel Syndrome

MalaCards organs/tissues related to Irritable Bowel Syndrome:

41
Colon, Testes, Brain, Small Intestine, Kidney, Liver, Heart

Publications for Irritable Bowel Syndrome

Articles related to Irritable Bowel Syndrome:

(show top 50) (show all 1088)
# Title Authors Year
1
Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome. ( 29911328 )
2018
2
Risk of psychiatric disorders in irritable bowel syndrome-A nationwide, population-based, cohort study. ( 29920876 )
2018
3
Functional Dyspepsia and Irritable Bowel Syndrome: Beyond Rome IV. ( 29421792 )
2018
4
The gut microbiome and irritable bowel syndrome: State of art review. ( 29935865 )
2018
5
A 8-year population-based cohort study of irritable bowel syndrome in childhood with history of atopic dermatitis. ( 29374025 )
2018
6
Obesity and irritable bowel syndrome: coincidence or association? ( 29922769 )
2018
7
Prevalence of Fructose Malabsorption in Patients With Irritable Bowel Syndrome After Excluding Small Intestinal Bacterial Overgrowth. ( 29433301 )
2018
8
The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. ( 29445178 )
2018
9
Shuganyin decoction improves the intestinal barrier function in a rat model of irritable bowel syndrome induced by water-avoidance stress. ( 29434653 )
2018
10
Perceived Stress, Its Physiological Correlates, and Quality of Life in Patients With Irritable Bowel Syndrome. ( 29402137 )
2018
11
Food consumption and dietary intakes in 36,448 adults and their association with irritable bowel syndrome: Nutrinet-SantAc study. ( 29399039 )
2018
12
<i>trans</i>-Resveratrol Ameliorates Stress-Induced Irritable Bowel Syndrome-Like Behaviors by Regulation of Brain-Gut Axis. ( 29962949 )
2018
13
Irritable Bowel Syndrome with predominant diarrhea and giardiasis: is it one or the other? ( 29500067 )
2018
14
Escherichia coli Nissle 1917 restores epithelial permeability alterations induced by irritable bowel syndrome mediators. ( 29956419 )
2018
15
Irritable bowel syndrome and functional dyspepsia: what can epidemiology tell us about etiology? ( 29774764 )
2018
16
Increased prevalence of rare sucrase-isomaltase (SI) pathogenic variants in irritable bowel syndrome patients. ( 29408290 )
2018
17
The Emerging Role of Mast Cells in Irritable Bowel Syndrome. ( 29942225 )
2018
18
Altered Intestinal Microbiota with Increased Abundance of <i>Prevotella</i> Is Associated with High Risk of Diarrhea-Predominant Irritable Bowel Syndrome. ( 29967640 )
2018
19
Sensitive bowel syndrome better than irritable bowel syndrome. ( 29426620 )
2018
20
Acupuncture for Diarrhoea-Predominant Irritable Bowel Syndrome: A Network Meta-Analysis. ( 29977312 )
2018
21
Research Design Characteristics of Published Pharmacologic Randomized Clinical Trials for Irritable Bowel Syndrome and Chronic Pelvic Pain Conditions: an Acttion Systemic Review. ( 29412183 )
2018
22
Relationship between sympathoadrenal and pituitary-adrenal response during colorectal distention in the presence of corticotropin-releasing hormone in patients with irritable bowel syndrome and healthy controls. ( 29979696 )
2018
23
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. ( 29950604 )
2018
24
Heat shock protein 70 protects mouse against post-infection irritable bowel syndrome via up-regulating intestinal I^I' T cell's Th17 response. ( 29928498 )
2018
25
High prevalence of irritable bowel syndrome-type symptoms in microscopic colitis: implications for treatment. ( 29977339 )
2018
26
Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) Study: Results of an Online Questionnaire. ( 29946799 )
2018
27
Efficacy and safety of Modified Tongxie Yaofang in diarrhea-predominant irritable bowel syndrome management: A meta-analysis of randomized, positive medicine-controlled trials. ( 29408906 )
2018
28
Comparison of Lactase Variant MCM6 -13910 C&amp;gt;T Testing and Self-report of Dairy Sensitivity in Patients With Irritable Bowel Syndrome. ( 29912753 )
2018
29
The importance of cluster analysis for enhancing clinical practice: an example from irritable bowel syndrome. ( 29447026 )
2018
30
Characteristics of the bacterial microbiome in association with common intestinal parasites in irritable bowel syndrome. ( 29915224 )
2018
31
Patients with primary restless legs syndrome have higher prevalence of autonomic dysfunction and irritable bowel syndrome. ( 29372261 )
2018
32
G protein beta 3(<i>GNI^3</i>) C825T polymorphism and irritable bowel syndrome susceptibility: an updated meta-analysis based on eleven case-control studies. ( 29416810 )
2018
33
Additional Glance on the Role of <i>Dientamoeba fragilis</i> &amp;amp; <i>Blastocystis hominis</i> in Patients with Irritable Bowel Syndrome. ( 29963091 )
2018
34
Chronic abdominal pain in irritable bowel syndrome - current and future therapies. ( 29957084 )
2018
35
Effect of<i>Lactobacillus rhamnosus</i>GG supernatant on serotonin transporter expression in rats with post-infectious irritable bowel syndrome. ( 29391756 )
2018
36
Gut Microbiota-Based Therapies for Irritable Bowel Syndrome. ( 29446765 )
2018
37
Advancements in drug development for diarrhea-predominant irritable bowel syndrome. ( 29451407 )
2018
38
Prevalence of sleep disorder in irritable bowel syndrome: A systematic review with meta-analysis. ( 29652034 )
2018
39
The prevalence of celiac disease in adult Chinese patients with diarrhea predominant irritable bowel syndrome of China, a prospective, controlled, cohort study. ( 29451364 )
2018
40
Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. ( 29980607 )
2018
41
The effect of fecal microbiota transplantation on psychiatric symptoms among patients with irritable bowel syndrome, functional diarrhea and functional constipation: An open-label observational study. ( 29684865 )
2018
42
To Understand the Modulatory Effect of Probiotics on Irritable Bowel Syndrome. ( 29955019 )
2018
43
The Role of Diet in the Treatment of Irritable Bowel Syndrome: A Systematic Review. ( 29413008 )
2018
44
Prevalence and Impact of Inflammatory Bowel Disease-Irritable Bowel Syndrome on Patient-reported Outcomes in CCFA Partners. ( 28092305 )
2017
45
Editorial: volatile organic compounds in irritable bowel syndrome - technology for an accurate and reliable point-of-care test? ( 28074509 )
2017
46
Intestinal microbiome-gut-brain axis and irritable bowel syndrome. ( 28887729 )
2017
47
The Place of Stress and Emotions in the Irritable Bowel Syndrome. ( 28061975 )
2017
48
Post-Infectious Irritable Bowel Syndrome. ( 28948467 )
2017
49
Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report. ( 28083815 )
2017
50
Overlap between irritable bowel syndrome and functional dyspepsia including subtype analyses. ( 28160607 )
2017

Variations for Irritable Bowel Syndrome

Expression for Irritable Bowel Syndrome

Search GEO for disease gene expression data for Irritable Bowel Syndrome.

Pathways for Irritable Bowel Syndrome

GO Terms for Irritable Bowel Syndrome

Cellular components related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 9.72 HTR3A HTR3E SLC6A4 TPH1 TRPV1
2 neuronal cell body GO:0043025 9.55 CCK CRH HTR3A TAC1 TRPV1
3 integral component of plasma membrane GO:0005887 9.28 CRHR1 CRHR2 HTR3A HTR3E HTR4 HTR7
4 intrinsic component of plasma membrane GO:0031226 9.13 CRHR1 TGM2 TRPV1
5 plasma membrane GO:0005886 10.07 CRHR1 CRHR2 HTR3A HTR3E HTR4 HTR7
6 extracellular region GO:0005576 10.02 CCK CHGA CRH IL10 MLN TAC1

Biological processes related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.92 CCK IL10 MLN TNF VIP
2 defense response to bacterium GO:0042742 9.84 CHGA IL10 TLR9 TNF
3 response to organic substance GO:0010033 9.77 IL10 SLC6A4 TNF
4 circadian rhythm GO:0007623 9.74 HTR7 SLC6A4 TPH1
5 inflammatory response GO:0006954 9.73 CRH IL10 TAC1 TLR9 TNF TRPV1
6 G-protein coupled receptor signaling pathway GO:0007186 9.61 CCK CRH CRHR1 CRHR2 HTR4 HTR7
7 negative regulation of growth of symbiont in host GO:0044130 9.58 IL10 TNF
8 response to molecule of bacterial origin GO:0002237 9.58 IL10 TLR9
9 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.56 IL10 TNF
10 parturition GO:0007567 9.55 CRH CRHR1
11 negative regulation of interleukin-6 production GO:0032715 9.54 IL10 TLR9 TNF
12 endothelial cell apoptotic process GO:0072577 9.51 IL10 TNF
13 negative regulation of cytokine secretion involved in immune response GO:0002740 9.48 IL10 TNF
14 negative regulation of interleukin-8 production GO:0032717 9.46 IL10 TLR9
15 cellular response to corticotropin-releasing hormone stimulus GO:0071376 9.43 CRHR1 CRHR2
16 receptor biosynthetic process GO:0032800 9.4 IL10 TNF
17 response to pain GO:0048265 9.33 CRH TAC1 TRPV1
18 positive regulation of corticosterone secretion GO:2000854 9.32 CRH TAC1
19 chemical synaptic transmission GO:0007268 9.1 CRH HTR3A HTR3E HTR4 HTR7 TAC1
20 signal transduction GO:0007165 10.15 CCK CRH CRHR1 CRHR2 HTR3A HTR3E

Molecular functions related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular ligand-gated ion channel activity GO:0005230 9.5 HTR3A HTR3E TRPV1
2 hormone activity GO:0005179 9.46 CCK CRH MLN VIP
3 neuropeptide hormone activity GO:0005184 9.43 CCK CRH VIP
4 serotonin binding GO:0051378 9.4 HTR3A HTR7
5 serotonin-gated cation-selective channel activity GO:0022850 9.37 HTR3A HTR3E
6 transmembrane signaling receptor activity GO:0004888 9.1 CRHR1 CRHR2 HTR3A HTR3E TLR9 TRPV1
7 corticotrophin-releasing factor receptor activity GO:0015056 8.96 CRHR1 CRHR2

Sources for Irritable Bowel Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....